HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Pediatrics
Sys. Review
Pleuropulmonary blastoma diagnosed after initial rhabdomyosarcoma interpretation in a 2-year-old boy
Case report shows rare lung cancer in toddler with DICER1
This case report describes a 2-year-old boy with a thoracic mass initially interpreted as embryonal rhabdomyosarcoma, later diagnosed as ple…
A toddler’s lung tumor was reclassified as a rare cancer linked to DICER1 syndrome, changing his treatment and highlighting a key diagnosis …
Frontiers
Jun 5, 2026
Oncology
Phase II
AN+AD combination therapy yields high response rates in nonbulky classical Hodgkin lymphoma patients
A New Treatment Path for Hodgkin Lymphoma Shows Stunning Success
This Phase 2 study evaluated AN+AD (brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine) in 154 patients with nonbulky classical Ho…
A promising new treatment approach for early-stage Hodgkin lymphoma is delivering remarkable results with less intensive chemotherapy.
Blood
Apr 12, 2026
Allergy & Immunology
Sys. Review
Case report and review of primary cervical melanoma shows inconsistent response to PD-1/PD-L1 inhibitors
Rare cervical melanoma cases show mixed results with immunotherapy and surgery
A case report of two patients with primary malignant melanoma of the cervix and a review of nine reported cases treated with PD-1/PD-L1 inhi…
Surgery alone fails for rare cervical melanoma, as 80% of patients progress on immunotherapy without chemotherapy or radiation.
Frontiers
Apr 9, 2026
Dermatology
Phase II
Phase II trial compares IMCgp100 vs investigator choice in advanced uveal melanoma
Can a new drug help people with a rare eye cancer live longer?
This Phase II study evaluated IMCgp100 versus investigator's choice (dacarbazine, ipilimumab, or pembrolizumab) in HLA-A*0201 positive adult…
A new drug for advanced eye cancer is being compared to standard treatments to see if it helps patients with a specific genetic marker live …
CT.gov
Mar 30, 2026